Drug Trial Radar · NCT04003389
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,831
Actual
Start
Jul 10, 2019
Primary completion
Jan 4, 2022
Study completion Jan 4, 2022
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the "adverse events." Those were the side effects that study participants had while they were in the study. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks. This study was "double-blinded." That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo). At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed. The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.
Conditions
- Hot Flashes
Interventions
fezolinetantDrug
administered orally
placeboDrug
administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
- Number of Participants With Mild, Moderate and Severe TEAETime frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
- Percentage of Participants With Endometrial HyperplasiaTime frame: Baseline Up to 52 weeks
- Percentage of Participants With Endometrial CancerTime frame: Baseline Up to 52 weeks
Locations
182 sites in 8 countries. Site status is shown where the registry gives one.
SEC Clinical Research
Andalusia, Alabama
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Achieve Clinical Research, LLC
Ensley, Alabama
Mesa Obstetricians and Gynecologists
Mesa, Arizona
Medpharmics LLC
Phoenix, Arizona
Precision Trials
Phoenix, Arizona
Del Sol Research Management
Tucson, Arizona
Visions Clinical Research - Tuscon
Tucson, Arizona
Eclipse Clinical Research
Tucson, Arizona
Hope Research Institute
Canoga Park, California
Alliance Research Inc
Canoga Park, California
Marvel Clinical Research
Huntington Beach, California
Grossmont Center for Clinical Research
La Mesa, California
Downtown L.A. Research Center, Inc.
Los Angeles, California
National Research Institute - Panorama
Los Angeles, California
Excell Research
Oceanside, California
Clinical Trials Research
Sacramento, California
Northern California Research
Sacramento, California
Wake Research Associates, LLC
San Diego, California
Women's Healthcare Affiliates
San Diego, California
CITrials, Inc
Santa Ana, California
Millennium Clinical Trials
Thousand Oaks, California
Women's Medical Group of Upland
Upland, California
Bayview Research Group
Valley Village, California
Downtown Women's Health Care
Denver, Colorado
Horizons Clincial Research Center LLC
Denver, Colorado
Coastal Connecticut Research, LLC
New London, Connecticut
Emerson Clinical Research institute
Washington D.C., District of Columbia
Olympian Clinical Research
Clearwater, Florida
Precision Clinical Research
Coral Springs, Florida
Nature Coast Clinical Research
Crystal River, Florida
Avail Clinical Research, LLC
DeLand, Florida
Universal Axon Clinical Research
Doral, Florida
Fleming Island Center for Clinical Research
Fleming Island, Florida
Clinical Physiology Associates
Fort Myers, Florida
Florida Medical Research
Gainesville, Florida
Vital Pharma Research Inc.
Hialeah, Florida
Health Awareness
Jupiter, Florida
Multi-Specialty Research Associates, Inc.
Lake City, Florida
Showing 40 of 182 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.